Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Novartis Pharma Services AG
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
A clinical study of the compound MCS110 in combination with the compound PDR001 in patients with advanced cancers
Phase Ib part: To characterize the safety and tolerability of MCS110 given in combination with PDR001 and to identify a recommended dose combination for Phase II. Phase II part: To estimate the...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
A phase II, open-label, multi-centre, single-arm study, evaluating the efficacy of Glivec® plus Hydroxyurea (HU) in patients with progressive glioblastoma multiforme (GBM), not receiving enzyme inducing anticonvulsant drugs (EIACDs)
To assess the clinical efficacy of the combined treatment of imatinib plus HU based on the objective overall response (OR) rate.This objective overall response rate is calculated as the rate of best ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
A multicenter, randomized, blinded efficacy and safety study of pasireotide LAR vs octreotide LAR in patients with metastatic carcinoid tumors whose disease-related symptoms are inadequately controlled by somatostatin analogues
Compare the long term efficacy of pasireotide LAR vs. octreotide LAR at month 6 in controlling diarrhea and/or flushing in patients with metastatic carcinoid tumors whose disease-related symptoms are ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
Study to compare Pre-discharge and Post-discharge treatment initiation with LCZ696 therapy in heart failure patients with reduced ejection fraction (HF-rEF) after an acute decompensation event
the primary objective of this study is to evaluate the proportion of patients in the Pre- and Post-discharge treatment initiation groups achieving the target dose of 200 mg LCZ696 twice daily at the e...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
A randomized, partially-blinded, single-dose, 4-way crossover study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally inhaled indacaterol maleate administered via the Concept1 device or as a PulmoSphere® formulation via the Simoon device
To assess the bronchodilator effect of an orally inhaled indacaterol maleate PulmoSphere® formulation in patients with persistent asthma compared with placebo as measured by mean change in FEV1 from b...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
Study of efficacy and safety of NVA237 in patients with poorly controlled asthma
To demonstrate the superiority of NVA237 50 μg o.d. compared to placebo in addition to background therapy with LABA/ ICS (≥ 800 μg/day of budesonide or equivalent) in terms of trough FEV1 (the mean of...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
Study of efficacy and safety of QVA149 compared to standard of care, a combination of fluticasone/salmeterol, in patients with moderate to severe COPD
To demonstrate the superiority of QVA149 as compared to fluticasone/salmeterol in COPD patients with moderate to severe airflow limitation in terms of standardized FEV1 AUC0-12h at 12 weeks of treatme...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
A multi-centre, randomized, double-blind, parallel group, active and placebo controlled, Proof of Concept study in patients with acute migraine to assess the efficacy, safety and tolerability of single oral doses of BGG492
•To assess the efficacy of a single dose of BGG492 vs. placebo in patients with acute migraine using the Migraine Patient Diary •To evaluate the safety and tolerability of single oral doses of 250 m...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
Study of efficacy and safety of secukinumab in subjects with moderate to severe chronic plaque-type psoriasis
To demonstrate the superiority of secukinumab in subjects with moderate to severe chronic plaque-type psoriasis in terms of both PASI 75 and IGA mod 2011 0 or 1 response (co-primary endpoints) at Week...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
A 52-week, multi-center, randomized, double-blind, placebo-controlled, time-lagged, parallel group study in patients with mild to moderate Alzheimer's Disease (AD) to investigate the safety, tolerability and Abeta-specific antibody response following three subcutaneous injections of CAD106
To evaluate safety and tolerabiltiy of repeated subcutaneous injections of CAD106 in patients with mild to moderate Alzheimer's disease. To determine time-course and decline, and isotype switch from...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
17
18
19
20
21
22
23
24
25
26
Next